Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

PURPOSE: Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined. METHOD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Oncol
Hauptverfasser: Zhai, Yujia, Yuan, Dai, Ge, Xueling, Hu, Shunfeng, Li, Peipei, Fang, Xiaosheng, Li, Ying, Zhou, Xiangxiang, Wang, Xin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2021
Schlagworte:
Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8030239/
https://ncbi.nlm.nih.gov/pubmed/33842312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.597453
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge